Price Action Alert: What’s Ahead for Ocular Therapeutix Inc After Today’s Significant Increase?

Price Action Alert: What's Ahead for Ocular Therapeutix Inc After Today's Significant Increase?

The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) is a huge mover today! About 427,391 shares traded hands. Ocular Therapeutix Inc (NASDAQ:OCUL) has declined 24.70% since April 22, 2016 and is downtrending. It has underperformed by 30.11% the S&P500.
The move comes after 8 months positive chart setup for the $296.77 million company. It was reported on Nov, 25 by Barchart.com. We have $12.04 PT which if reached, will make NASDAQ:OCUL worth $8.90 million more.

Analysts await Ocular Therapeutix Inc (NASDAQ:OCUL) to report earnings on March, 9. They expect $-0.47 earnings per share, down 9.30% or $0.04 from last year’s $-0.43 per share. After $-0.39 actual earnings per share reported by Ocular Therapeutix Inc for the previous quarter, Wall Street now forecasts 20.51% negative EPS growth.

Ocular Therapeutix Inc (NASDAQ:OCUL) Ratings Coverage

Out of 4 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ocular Therapeutix has been the topic of 8 analyst reports since August 5, 2015 according to StockzIntelligence Inc. Morgan Stanley downgraded the shares of OCUL in a report on Friday, October 23 to “Equal-Weight” rating. Nomura initiated the stock with “Buy” rating in Wednesday, August 5 report. Morgan Stanley maintained the shares of OCUL in a report on Tuesday, June 7 with “Overweight” rating. RBC Capital Markets maintained Ocular Therapeutix Inc (NASDAQ:OCUL) rating on Tuesday, November 15. RBC Capital Markets has “Outperform” rating and $32 price target. The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) has “Overweight” rating given on Thursday, February 18 by Morgan Stanley. The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) has “Overweight” rating given on Thursday, April 28 by Morgan Stanley. The company was initiated on Thursday, August 11 by JMP Securities. As per Thursday, August 13, the company rating was initiated by Morgan Stanley.

According to Zacks Investment Research, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts.”

Another recent and important Ocular Therapeutix Inc (NASDAQ:OCUL) news was published by Investorplace.com which published an article titled: “Why CSX Corporation (CSX), Ocular Therapeutix Inc (OCUL), and Ulta Salon …” on October 13, 2016.

OCUL Company Profile

Ocular Therapeutix, Inc., incorporated on September 12, 2006, is a biopharmaceutical company. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. The Company’s hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment